← 返回

免疫治疗的希望与风险

英文原题:The promise and perils of immunotherapy.

查看英文原题

The promise and perils of immunotherapy.

PubMed 2021/09/28(内容时间) Blood Adv Q1 · IF 7.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

对免疫系统无法控制肿瘤生长或预防自身免疫的机制理解的进展,推动了治疗这些疾病的强效治疗策略的开发。与传统具有广泛抑制作用的疗法不同,免疫疗法更类似于靶向治疗,因为它们由机制驱动,并且通常以“药物化”特定潜在通路或表型为目标进行开发。这意味着它们的作用和毒性,至少在理论上,更容易预测。功能化抗体、基因工程 T 细胞和免疫检查点抑制剂的开发持续加速,揭示了新的生物学机制并为患者带来了新的治疗。在以下部分中,我们概述免疫治疗概念,重点介绍免疫治疗领域的近期进展,并讨论争议和未来方向,特别是与血液肿瘤学或血液相关疾病有关的内容。最后,我们说明本刊发表的原创研究如何融入并促进免疫治疗进展的总体框架。

展开英文摘要原文

Advances in understanding the ways in which the immune system fails to control tumor growth or prevent autoimmunity have led to the development of powerful therapeutic strategies to treat these diseases. In contrast to conventional therapies that have a broadly suppressive effect, immunotherapies are more akin to targeted therapies because they are mechanistically driven and are typically developed with the goal of "drugging" a specific underlying pathway or phenotype.

This means that their effects and toxicities are, at least in theory, more straightforward to anticipate. The development of functionalized antibodies, genetically engineered T cells, and immune checkpoint inhibitors continues to accelerate, illuminating new biology and bringing new treatment to patients.

In the following sections, we provide an overview of immunotherapeutic concepts, highlight recent advances in the field of immunotherapies, and discuss controversies and future directions, particularly as these pertain to hematologic oncology or blood-related diseases.

We conclude by illustrating how original research published in this journal fits into and contributes to the overall framework of advances in immunotherapy.

论文信息

作者
Lesch S、Gill S
单位
Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA; and.United States
文献类型
非美国政府资助研究 · 综述
期刊
Blood advances2021 Sep 28
原文标识
PubMed 34581774 · DOI 10.1182/bloodadvances.2021004453C